Search results for "Antipsychotics"

showing 10 items of 23 documents

Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone p…

2018

BACKGROUND Long-acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients with schizophrenia. OBJECTIVE The objective of this study was to assess the predictive factors of better overall functioning in patients with chronic schizophrenia and schizoaffective disorder treated with PAL and ARI. METHOD Enrolled were 143 (97 males, 46 females, mean age 38.24 years, SD = 12.65) patients with a diagnosis of schizophrenia or schizoaffective disorder, whom we allocated in two gr…

AdultMalemedicine.medical_specialtyaripiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; neurology; neurology (clinical); psychiatry and mental health; pharmacology (medical)Global Assessment of FunctioningAripiprazoleSchizoaffective disorderPharmacyOutcome Assessment (Health Care)03 medical and health sciencesYoung Adult0302 clinical medicineglobal assessment of functioningInternal medicineOutcome Assessment Health CarePaliperidone PalmitatemedicineHumansPharmacology (medical)aripiprazole monohydratearipiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Young Adult; Outcome Assessment (Health Care)Paliperidone Palmitatebusiness.industrylong-acting injectable antipsychoticsMiddle Agedschizoaffective disordermedicine.disease030227 psychiatryPsychiatry and Mental healthNeurologyPsychotic DisordersSchizophreniaDelayed-Action PreparationsSettore SECS-P/03 - Scienza delle FinanzeSchizophreniaChronic schizophreniaAripiprazoleFemaleNeurology (clinical)business030217 neurology & neurosurgeryDiagnosis of schizophreniamedicine.drugAntipsychotic AgentsHuman psychopharmacology
researchProduct

Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophreniaspectrum disorders: Findings f…

2020

This study, based on the 'Servizi Territoriali Associati per la Ricerca' (STAR) Network Depot Study nationwide baseline data, explored whether individual symptoms severity and clusters might influence the prescription of paliperidone palmitate 1-month (PP1M) vs. aripiprazole monohydrate. The Brief Psychiatric Rating Scale (BPRS) was used to assess psychopathology and relevant symptoms clusters. Drug Attitude Inventory, 10 items, was used to test attitude towards medications. Adherence to treatments was rated according to the Kemp seven-point scale. We assessed for eligibility 451 individuals and, among them, we included 195 subjects (n = 117 who started PPM1 and n = 78 aripiprazole monohydr…

Aripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate; Schizophrenia; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Knowledge Attitudes Practice; Humans; Male; Medication Adherence; Paliperidone Palmitate; Practice Patterns Physicians'; Schizophrenia; Schizophrenic Psychology; Young AdultAdultMaleLong-acting injectable antipsychoticmedicine.medical_specialtyHealth Knowledge Attitudes Practicemedicine.medical_treatmentAripiprazole monohydrate Long-acting injectable antipsychotics Paliperidone palmitate SchizophreniaAripiprazolePractice PatternsLong-acting injectable antipsychoticsMedication Adherence03 medical and health sciencesYoung Adult0302 clinical medicineAripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate; SchizophreniaInternal medicineBrief Psychiatric Rating ScalemedicineHumansPharmacology (medical)Practice Patterns Physicians'AntipsychoticSettore MED/25 - PsichiatriaPaliperidone PalmitatePaliperidone palmitatePracticePhysicians'business.industryHealth KnowledgeAripiprazole monohydratemedicine.disease030227 psychiatryPsychiatry and Mental healthSchizophreniaAttitudesPropensity score matchingSchizophreniaObservational studyAripiprazoleFemaleSchizophrenic Psychologybusiness030217 neurology & neurosurgerymedicine.drugPsychopathologyAntipsychotic Agents
researchProduct

Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.

2016

Second-generation antipsychotics (SGAs) are frequently co-prescribed with drug metabolic inducers and inhibitors. SGA pharmacokinetic drug-drug interactions (DDIs) with inducers and inhibitors have not received enough attention in the literature but can be studied in by using therapeutic drug monitoring (TDM).The limited information available on oral SGA pharmacokinetic DDIs is reviewed. A systematic literature search on the available oral SGA TDM studies is completed. By integrating TDM studies with the information on in vitro metabolism studies, case report/series and prospective studies, a table is provided to manage average SGA patients taking inducers or inhibitors by using TDM and/or …

DrugDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjecttherapeutic drug monitoringAdministration OralPharmacologyToxicology030226 pharmacology & pharmacyDrug interactions03 medical and health sciences0302 clinical medicinePharmacokineticsinhibitorsMedicineHumansProspective cohort studyClozapinemedia_commonLurasidoneinducersPharmacologyRisperidonemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industrysecond-generation antipsychoticsGeneral MedicineDrug interactions; inducers; inhibitors; pharmacokinetics; second-generation antipsychotics; therapeutic drug monitoring030227 psychiatryTherapeutic drug monitoringQuetiapineAntidepressive Agents Second-GenerationDrug Monitoringbusinesspharmacokineticsmedicine.drugAntipsychotic Agents
researchProduct

Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice

2010

Pharmacokinetic interactions, e.g. modulation of drug transporters like P-glycoprotein at the blood-brain barrier, can be a reason for treatment non-response. This study focuses on the influence of induction of drug transporters on the disposition of the antipsychotic drugs risperidone and 9-hydroxyrisperidone. Brain and serum concentrations of risperidone and its active metabolite 9-hydroxyrisperidone, which are known P-glycoprotein substrates, were measured after drug transporter induction with rifampicin, dexamethasone or 5-pregnene-3beta-ol-20-on-16alpha-carbonitrile using high performance liquid chromatography. Disposition of risperidone and 9-hydroxyrisperidone was dramatically decrea…

Drugmedia_common.quotation_subjectmedicine.medical_treatmentlcsh:RS1-441Pharmaceutical ScienceP-glycoproteinPharmacologyArticlelcsh:Pharmacy and materia medicaPharmacokineticsMedicineAntipsychoticDexamethasoneActive metaboliteP-glycoproteinmedia_commonrisperidoneRisperidonebiologybusiness.industryTransporterdrug transporterantipsychoticsdispositionbiology.protein9-hydroxyrisperidonebusinessmedicine.drugPharmaceutics
researchProduct

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.

2021

Introduction The aim of this study was to describe the number and type of drugs used to treat depressive disorders in inpatient psychiatry and to analyse the determinants of potential drug-drug interactions (pDDI) and potentially inappropriate medication (PIM). Methods Our study was part of a larger pharmacovigilance project funded by the German Innovation Funds. It included all inpatients with a main diagnosis in the group of depressive episodes (F32, ICD-10) or recurrent depressive disorders (F33) discharged from eight psychiatric hospitals in Germany between 1 October 2017 and 30 September 2018 or between 1 January and 31 December 2019. Results The study included 14,418 inpatient cases.…

Epidemiologymedicine.medical_treatment0302 clinical medicineRisk FactorsMedicine and Health SciencesAntipsychoticsDrug Interactions030212 general & internal medicineDepression (differential diagnoses)Potentially Inappropriate Medication Listmedia_commonMultidisciplinaryDepressionPharmaceuticsQRDrugsAntidepressantsMiddle AgedAntidepressive AgentsAntidepressant Drug TherapyMedicineAntidepressantDrug Therapy CombinationAntipsychotic AgentsResearch ArticleDrugNeurological Drug Therapymedicine.medical_specialtyPatientsSciencemedia_common.quotation_subject03 medical and health sciencesPharmacotherapyDrug TherapyInternal medicinePharmacovigilanceMental Health and PsychiatrymedicineHumansAntipsychoticProbabilityPolypharmacyPharmacologyInpatientsbusiness.industryMood DisordersOdds ratioHealth CareLogistic ModelsMedical Risk Factorsbusiness030217 neurology & neurosurgeryReceptor Antagonist TherapyPloS one
researchProduct

Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy

2018

Background For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed predominantly to chronic and severe patients, as a last resort when other treatments failed. Recently, a broader and earlier use of LAIs, particularly second-generation LAIs, has been emphasized. To date, few studies attempted to frame how this change in prescribing took place in real-world practice. Therefore, this study aimed to describe the clinical features of patients prescribed with LAIs, and to explore possible prescribing differences between first- and second-generations LAIs under ordinary clinical practice in Italy. Methods The STAR Network "Depot" Study is an observational, longitudinal…

Genetics and Molecular Biology (all)MalePediatricsEuropean PeopleBipolar DisorderCross-sectional studyEconomicsEpidemiologymedicine.medical_treatmentassessmentviruseslcsh:MedicineSocial SciencesLongitudinal StudieBiochemistryPrescriptionGeographical locations0302 clinical medicineMathematical and Statistical TechniquesBiochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)immune system diseasesEpidemiologyMedicine and Health Scienceslong-acting intramuscular (LAI) antipsychotics; clinical practice; assessment; second-generation antipsychotic (SGA) LAIsAntipsychoticsEthnicitiesLongitudinal Studieslcsh:ScienceMultidisciplinaryvirus diseasesDrugsMiddle Agedclinical practiceItalian PeopleEuropePrescriptionsItalyPhysical SciencesAripiprazoleFemaleBivariate AnalysisStatistics (Mathematics)medicine.drugHumanResearch ArticleAntipsychotic AgentsEmploymentAdultmedicine.medical_specialtyAdolescentResearch and Analysis Methods03 medical and health sciencesMental Health and PsychiatrymedicineHumansPaliperidoneBipolar disorderEuropean UnionStatistical MethodsAntipsychoticCross-Sectional StudiePharmacologyRisperidoneBiochemistry Genetics and Molecular Biology (all)business.industryMood Disorderslcsh:Rmedicine.disease030227 psychiatryAntipsychotic AgentCross-Sectional StudiesAgricultural and Biological Sciences (all)Labor EconomicsMultivariate AnalysisSchizophreniaObservational studylcsh:QPopulation Groupingslong-acting intramuscular (LAI) antipsychoticsPeople and placesbusiness030217 neurology & neurosurgerysecond-generation antipsychotic (SGA) LAIsMathematicsPLoS ONE
researchProduct

Adjunctive clotiapine for the management of delusions in two adolescents with anorexia nervosa

2021

Clotiapine is an atypical antipsychotic indicated for the management of a series of acute psychotic disorders. The current literature lacks evidence concerning the tolerability and clinical use of this drug in the management of individuals with anorexia nervosa (AN). In this study, we report two cases of adolescents with AN, treated with clotiapine. The reason for the administration of clotiapine was, for both patients, the manifestation of bizarre delusions concerning food and calories. Patient 1 presented a presyncope after the first dose of clotiapine, and treatment was rapidly discontinued. Patient 2 was treated with clotiapine for 9 months; doses were titrated from 20 mg/day to 70 mg/d…

Inpatient treatmentAnorexia nervosaDevelopmentAdolescentsArticleBF1-990Behavioral Neuroscienceclotiapine; anorexia nervosa; eating disorders; adolescents; inpatient treatment; antipsychoticseating disorderadolescentGeneticsEating disordersPsychologyAntipsychoticsGeneral PsychologyEcology Evolution Behavior and SystematicsClotiapine
researchProduct

Off-label long acting injectable antipsychotics in real-world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Ne…

2022

Introduction: Information on the off–label use of Long–Acting Injectable (LAI) antipsychotics in the real world is lacking. In this study, we aimed to identify the sociodemographic and clinical features of patients treated with on– vs off–label LAIs and predictors of off–label First– or Second–Generation Antipsychotic (FGA vs. SGA) LAI choice in everyday clinical practice. Method: In a naturalistic national cohort of 449 patients who initiated LAI treatment in the STAR Network Depot Study, two groups were identified based on off– or on–label prescriptions. A multivariate logistic regression analysis was used to test several clinically relevant variables and identify those associated with th…

Long-acting injectable antipsychoticCross-Sectional StudiesOff-labelPersonality disorderBipolar disorderDelayed-Action PreparationsSchizophreniaHumansBipolar disorder; Long-acting injectable antipsychotics; Off-label; Personality disorder; Schizophrenia; Cross-Sectional Studies; Delayed-Action Preparations; Humans; Off-Label Use; Antipsychotic Agents; SchizophreniaOff-Label UseSettore MED/25 - PsichiatriaLong-acting injectable antipsychoticsAntipsychotic Agents
researchProduct

Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disor…

2022

In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement (p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with…

Long-acting injectable antipsychoticPaliperidone palmitate 1-monthAripiprazoleAripiprazole monohydrateLong-acting injectable antipsychoticsPsychiatry and Mental healthPaliperidone PalmitateSchizophreniaHumansProspective StudiesSettore MED/25 - PsichiatriaBiological PsychiatryAripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate 1-monthAntipsychotic Agents
researchProduct

Oral lichenoid drug reaction by lithium in a patient with bipolar disorder

2005

Bipolar disorder (BD) is a psychiatric disease characterized by recurrent and alternated episodes of depression and mania. For the treatment of BD, anticonvulsants drugs as lithium, carbamazepine and oxcarbazepine can be used. These drugs can be associated with potential adverse effects: weight gain, tremors, thyroid abnormalities, and cognitive, gastrointestinal, cardiac or dermatological problems. We describe a case of BD with oral lichenoid drug reaction probably because of the mood stabilizers.

MaleCancer Researchmedicine.medical_specialtyBipolar DisorderLichenoid EruptionsLithium (medication)antipsychotics bipolar disorders drug reaction lichenoid lesions lithium therapyPathology and Forensic Medicinechemistry.chemical_compoundLithium CarbonateAntimanic Agentsmental disordersmedicineHumansBipolar disorderOxcarbazepineAdverse effectbusiness.industryLithium carbonateCarbamazepineMiddle Agedmedicine.diseaseDermatologySurgeryOtorhinolaryngologychemistryLichenoid eruptionPeriodonticsOral Surgerymedicine.symptomMouth DiseasesbusinessManiamedicine.drugJournal of Oral Pathology and Medicine
researchProduct